Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, August 31, 2021 11:43:13 AM
https://finance.yahoo.com/news/canonic-announces-pre-launch-first-110000986.html
Pre-launch of G-nnovation product line to a limited number of patients:
Full commercial launch expected in 2022
REHOVOT, Israel, Aug. 31, 2021 /PRNewswire/ -- Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the pre-launch of its first-generation medical cannabis inflorescence products.
Canonic's first product line, G-nnovation, is based on cannabis varieties that were selected and developed to express high levels of THC[1] and premium consumer traits. As part of the pre-launch, G-nnovation products will be marketed in Israel to a limited number of licensed patients through Telepharma pharmacy, with whom Canonic recently engaged. Full commercial product launch in Israel is expected in 2022.
The pre-launch follows the successful completion of selection and development of the first-generation G-nnovation product line under Canonic's Meta Yield product program, the approval of The Israel Medical Cannabis Authority (IMCA) of the product files, and the establishment of commercialization channels. With this, Canonic has completed its end-to-end cannabis value chain in Israel, from seed to product.
According to recent statistics, in July 2021 there were approximately 100,000 licensed patients in Israel that consumed approximately 20 tons of cannabis in the first 6 months of the year[2], with a total medical cannabis market in Israel estimated at $260 million per year[3]. According to industry estimates, based on current growth rates, the Israeli market will reach approximately 250,000 patients by 2025.[4]
Dr. Arnon Heyman, CEO of Canonic stated: "We are very excited to launch our first products in the Israeli market. We achieved this milestone in a very short time due to our experienced team and strong computational biology capabilities. I see this as our first step in fulfilling our vision to become a leading global medical cannabis company. The initial launch in the Israeli market is only the beginning of our journey towards penetration to additional markets abroad."
Mr. Ofer Haviv, Chairman of Canonic and CEO & President of Evogene, stated: "I am pleased to see that within a very short time, Canonic has built an impressive operation, which we expect will come into full fruition in 2022 with first commercial scale sales of medical cannabis in Israel. This milestone was achieved, in part, by using Evogene's platform with its unique computational capabilities in the field of genomics, namely the GeneRator AI tech engine."
About Canonic Ltd.:
Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), developing medical Cannabis products utilizing a Computational Predictive Biology (CPB) platform. The Company's products in development are aimed at improving active compounds yield, genetic stability and Cannabis varieties for specific medical indications. The Company's strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical Cannabis products. For more information, please visit: https://www.canonicbio.com/.
Recent EVGN News
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 09/19/2024 08:15:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/17/2024 11:00:12 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 08:01:22 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 09/04/2024 11:00:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/26/2024 01:30:23 PM
- Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 08/23/2024 12:55:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/23/2024 12:50:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/22/2024 11:00:28 AM
- Evogene Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/22/2024 11:00:00 AM
- Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • PR Newswire (US) • 08/12/2024 11:11:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/12/2024 11:01:49 AM
- Evogene Schedules Second Quarter 2024 Financial Results Release • PR Newswire (US) • 08/12/2024 11:00:00 AM
- Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil • PR Newswire (US) • 07/31/2024 11:00:00 AM
- Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split • PR Newswire (US) • 07/23/2024 12:48:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/23/2024 11:00:10 AM
- ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants • PR Newswire (US) • 07/17/2024 12:00:00 PM
- Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat • PR Newswire (US) • 07/02/2024 11:00:00 AM
- Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country • PR Newswire (US) • 06/25/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/17/2024 08:10:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/06/2024 08:02:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 03:00:08 PM
- Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma • PR Newswire (US) • 05/23/2024 03:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 11:00:23 AM
- Evogene Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds • PR Newswire (US) • 05/21/2024 11:03:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM